CEL SCI CORP (CVM): Submission of Matters to a Vote of Security Holders
CEL SCI CORP (CVM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cvm_8k.htm 0000725363 false 0000725363 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da
How this was made
The 30-second read
Why it matters
This is primarily a corporate governance and compensation-plan disclosure. It can influence dilution expectations and governance optics, but it does not introduce new clinical, regulatory, or financial catalysts.
Market read
Shareholder voting results confirm the board slate and approval of 2026 equity compensation plans, with limited immediate trading implications absent additional plan details or new business developments.
What to watch
Traders may focus on whether the approved plans increase future share issuance/dilution, but the filing provides vote totals rather than plan size, grant limits, or expected issuance.
Background
The company’s annual shareholder meeting was held Aug 14, 2026, and this 8-K reports the results of director elections and several advisory and ratification proposals.
Ticker impact
CEL-SCI filed an 8-K reporting shareholder votes on director elections and adoption of its 2026 stock option and stock bonus plans.
Low near-term impact; any move is likely limited to sentiment around dilution/governance rather than fundamentals.
Item 5.07 is a routine post-meeting voting results disclosure. It is time-stamped and company-specific, but it does not include new earnings, trial data, financing terms, or material strategic transactions.
Market effects
Minimal. Equity-plan approvals are common among small-cap biotech issuers and do not, by themselves, change sector fundamentals.
None.
None.
Counterpoint
Even without new fundamentals, equity-plan approvals can signal management intent to increase hiring/retention via equity, which may matter for valuation in thinly traded names.
Key entities
- issuerCEL-SCI Corporation
NYSE American-listed company filing the 8-K with shareholder voting results.
- executiveGeert Kersten
Elected as a director at the Aug 14, 2026 shareholder meeting.
- auditorBDO USA, LLP
Ratified by shareholders as independent registered public accounting firm for fiscal year ending Sept 30, 2026.
